Literature DB >> 9974177

Cannabinoid transmission and pain perception.

B R Martin1, A H Lichtman.   

Abstract

The use of cannabis for the management of a wide range of painful disorders has been well documented in case reports throughout history. However, clinical evaluations of cannabis and its psychoactive constituent THC have not led to a consensus regarding their analgesic effectiveness. On the other hand, THC and its synthetic derivatives have been shown to be effective in most animal models of pain. These antinociceptive effects are mediated through cannabinoid receptors in the brain that in turn appear to interact with noradrenergic and kappa opioid systems in the spinal cord to modulate the perception of painful stimuli. The endogenous ligand, anandamide, is also an effective antinociceptive agent. The extent to which the endogenous cannabinoid system is involved in the modulation of pain is currently unknown.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9974177     DOI: 10.1006/nbdi.1998.0218

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  19 in total

Review 1.  How might cannabinoids influence sexual behavior?

Authors:  N Stella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 2.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

3.  Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.

Authors:  Shao M Tham; James A Angus; Elizabeth M Tudor; Christine E Wright
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 4.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

5.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

Review 6.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

7.  Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Christian A Kell; Ulrike Nöth; Johannes Vermehren; Jochen Kaiser; Ralf Deichmann; Jörn Lötsch
Journal:  Neuropsychopharmacology       Date:  2015-10-30       Impact factor: 7.853

Review 8.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test.

Authors:  Maria Flavia Barbano; Anna Castañé; Elena Martín-García; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2009-05-19       Impact factor: 4.530

10.  Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.

Authors:  Ronald J Ellis; Will Toperoff; Florin Vaida; Geoffrey van den Brande; James Gonzales; Ben Gouaux; Heather Bentley; J Hampton Atkinson
Journal:  Neuropsychopharmacology       Date:  2008-08-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.